

## **Ad hoc Announcement Pursuant to § 15 WpHG (German Securities Trading Act): Epigenomics AG Plans Changes in the Composition and Size of its Supervisory Board**

*Berlin, Germany, March 16, 2012* – Epigenomics AG (ISIN: DE000A1K0516) today decided to propose to the shareholders of the company at the upcoming Annual General Meeting on May 2, 2012 to vote in favor of a reduction of the size of the Supervisory Board from currently six to three members. Furthermore, the company's Chairman, Prof. Dr. Dr. h.c. Rolf Krebs, announced that for personal reasons he will not stand for re-election at the upcoming Annual General Meeting.

Prof. Dr. Rolf Krebs (72) has been a member of the Supervisory Board of Epigenomics AG since 2000 and its Chairman since 2003. During this period, the company has evolved from a privately held start-up research company to a publicly listed, worldwide commercial leader in the field of blood based products for the early detection of cancer.

The Supervisory Board has further resolved to propose Mr. Heino von Prondzynski for election to the Supervisory Board by the Annual General Meeting. Mr. von Prondzynski has indicated his willingness to accept the role as Chairman of the Supervisory Board in case of his election.

Heino von Prondzynski (62) is an internationally recognized expert and accomplished business leader in the field of molecular diagnostics with an extensive network of contacts in the US, Europe and beyond. Among other career accomplishments, he has been CEO of the diagnostics division of F. Hoffmann-La Roche Ltd., Basel, Switzerland and a member of the group executive committee of Roche. He is intimately acquainted with the company, having been a member of the Supervisory Board of Epigenomics from May 2007 until March 2010.

In addition to Mr. von Prondzynski, current members of the Supervisory Board, Ms. Kessler, Ph.D. and Prof. Dr. Reiter, will be seeking election at the upcoming Annual General Meeting.

The proposed changes to the Supervisory Board structure and composition have been thoroughly planned and were made in line with last year's decision to reinforce the focus of the company's operations on the key US market. Heino von Prondzynski has indicated his intention to work closely with the management team to diligently explore all viable strategic options for the company in its further development, including, but not limited to, the possibility of securing additional financial resources to support the company's operations beyond the current cash reach. A main operational goal of the company remains to gain approval for and subsequently introduce Septin9 based colorectal cancer screening tests in the US market.

**- End of Ad hoc –**

## Contact Epigenomics AG

Antje Zeise CIRO  
Manager IR | PR  
Epigenomics AG  
Phone: +49 (0) 30 24345 386  
ir@epigenomics.com  
www.epigenomics.com

*Epigenomics' legal disclaimers. This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.*